AstraZeneca lands FDA approval for AKT inhibitor in biomarker-defined breast cancer subset
AstraZeneca has scored an FDA approval for its AKT inhibitor capivasertib, adding a new targeted therapy to its treatment offerings in breast cancer.
The drug, with the market name Truqap, is approved in combination with AstraZeneca’s own Faslodex (fulvestrant) to treat a subset of patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence within 12 months of completing adjuvant therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.